Details of the Drug Combinations

General Information of This Drug (ID: DM9OZWQ)

Drug Name

Lovastatin DM9OZWQ

Synonyms

lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[2]
Hyperlipidemia	5C80.Z	Approved	[1]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[1]
Hypertriglyceridemia	5C80.1	Approved	[1]
Melanoma	2C30	Approved	[1]
X-linked chondrodysplasia punctata 2	N.A.	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Phase 3	[3]
Smith-Lemli-Opitz syndrome	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticholesteremic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lovastatin + Idarubicin	DCRHWEN	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
------------------------------------------------------------------------------------

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lovastatin + Docetaxel	DC23MGG	Docetaxel	Any Cancer	[5]
Lovastatin + Interferon alfa-2B	DC9VG9D	Interferon alfa-2B	Melanoma	[6]
Lovastatin + Cytarabine	DCCRBNK	Cytarabine	Acute Myeloid Leukemia	[7]
Lovastatin + Colestipol	DCM6N9B	Colestipol	Cardiovascular Diseases	[8]
Lovastatin + Paclitaxel	DCVR76N	Paclitaxel	Ovarian Cancer	[9]
------------------------------------------------------------------------------------

References

1	Lovastatin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2739).
3	Clinical pipeline report, company report or official report of CardioPharma Wilmington.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT00584012) A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
6	ClinicalTrials.gov (NCT00963664) Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
7	ClinicalTrials.gov (NCT00583102) Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
8	ClinicalTrials.gov (NCT00000512) Familial Atherosclerosis Treatment Study
9	ClinicalTrials.gov (NCT00585052) A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer